Year 2013 has been called the year of the biotech return. According to BioTechNow, the sector is doing better than it has since 2007. One of the highlighted companies today, StemCells Inc. (STEM, Financial) just completed its successful IPO last week.
The GuruFocus Value Screen for finding 52-Week Lows shows the biotechnology sector with 25 companies out of 176 on a 52-week low. The low ratio is 0.14.
Here’s a look at three waning biotech companies and the billionaires who hold them. All companies selected are more than 42% off a 52-week high.
Highlight: AEterna Zentaris Inc. (AEZS, Financial)
The current AEZS share price is $1.47, or 57.4% off the 52-week high of $3.45.
Down 39% over 12 months, AEterna Zentaris Inc. has a market cap of $45.61 million, and trades at a P/B of 5.80.
Incorporated in 1990, AEterna Zentaris Inc. is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. The company’s product pipeline encompasses compounds at all stages of development from drug discovery through to marketed products.
The company reported revenue of $30.1 million for the quarter ending June 30, 2013, up from $7.5 million year over year. Net income for the quarter was reported at $9.3 million up from $4.5 million in the same quarter of 2012. Earnings for the second quarter of 2013 were $0.37 per basic and diluted share, up from $0.25 in the same quarter of 2012.
Guru Action: The top guru owner is Jim Simons with 376,650 shares as of the second quarter in 2013. His shares represent 1.21% of shares outstanding. In the second quarter of 2013, he reduced his position by 29.44% and averaged a loss of 22.2% on 157,168 shares sold at an average price of $1.89 per share.
His trading history shows five years of losses. Overall, he averaged a loss of 39% on 533,818 shares bought at an average price of $2.41 per share. He also lost 22% on 157,168 shares sold at an average price of $1.89 per share.
Check out the other guru stakeholder. There is no insider trading to report.
Historical share price, revenue and net income tracking:
Highlight: Amyris Inc. (AMRS, Financial)
The current AMRS share price is $2.38, or 42.7% off the 52-week high of $4.15.
Down 22% over 12 months, Amyris Inc. has a market cap of $181.39 million, and trades with a P/B of 8.68.
Formed in 2003, Amyris Inc. is a renewable products company that provides alternatives to petroleum-sourced products used in transportation fuel markets and specialty chemical. The company uses its proprietary synthetic biology platform to design microbes, primarily yeast organisms, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. These long-chain hydrocarbons are used in many products including cosmetics, lubricants, flavors and fragrances, polymers and plastic additives, home and personal care products and transportation fuels.
The company reported aggregate revenue of $10.8 million for the quarter ending June 30, 2013, down from $19.3 million year over year. The company reports a GAAP net loss of $38.9 million for the quarter, up from a loss of $46.8 million in the same quarter of 2012. The net loss attributable to common stockholders is reported at ($0.34 per share) for the second quarter of 2013.
Guru Action: The sole guru stakeholder, as of June 30, 2013, is Paul Tudor Jones with 11,600 shares or 0.02% of shares outstanding.
His trading history shows losses in seven out of seven quarters. Overall, he averaged a loss of 14% on 20,600 shares bought at an average price of $2.78 per share. He also lost 26% on 9,000 shares sold at an average price of $3.21 per share.
Check out the other guru histories and insider trading.
Historical share price, revenue and net income tracking:
Highlight: StemCells Inc. (STEM)
The current STEM share price is $1.43, or 42.8% off the 52-week high of $2.50.
Down 36% over 12 months, StemCells Inc. has a market cap of $59.07 million, and trades at a P/B of 6.89.
StemCells Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. The company’s primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents.
On Oct. 8, 2013, the company reported closing its $18.6 million public offering. Selling units at a public offering price of $1.45 per unit, StemCells Inc. received total proceeds of around $17.3 million after expenses, according to a company press release.
Guru Action: There is no recent guru action to report. Jim Simons sold out his holding in the first quarter of 2013. He took a loss of 19.2% on 24,300 shares sold at an average price of $1.77.
His trading history shows 11 losing quarters out of 13 quarters total. In the first and second quarters of 2012, he gained 44.4% and 72.3%, respectively.
Check out the histories of past guru stakeholders. There is no insider activity to report.
Historical share price, revenue and net income tracking since 1992:
If you are not yet a Premium Member, try a 7-day Free Trial.
Use the GuruFocus Value Screen to find 52-Week Lows and discover potentially deep value stocks held by billionaire Guru investors.
The GuruFocus Value Screen for finding 52-Week Lows shows the biotechnology sector with 25 companies out of 176 on a 52-week low. The low ratio is 0.14.
Here’s a look at three waning biotech companies and the billionaires who hold them. All companies selected are more than 42% off a 52-week high.
Highlight: AEterna Zentaris Inc. (AEZS, Financial)
The current AEZS share price is $1.47, or 57.4% off the 52-week high of $3.45.
Down 39% over 12 months, AEterna Zentaris Inc. has a market cap of $45.61 million, and trades at a P/B of 5.80.
Incorporated in 1990, AEterna Zentaris Inc. is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. The company’s product pipeline encompasses compounds at all stages of development from drug discovery through to marketed products.
The company reported revenue of $30.1 million for the quarter ending June 30, 2013, up from $7.5 million year over year. Net income for the quarter was reported at $9.3 million up from $4.5 million in the same quarter of 2012. Earnings for the second quarter of 2013 were $0.37 per basic and diluted share, up from $0.25 in the same quarter of 2012.
Guru Action: The top guru owner is Jim Simons with 376,650 shares as of the second quarter in 2013. His shares represent 1.21% of shares outstanding. In the second quarter of 2013, he reduced his position by 29.44% and averaged a loss of 22.2% on 157,168 shares sold at an average price of $1.89 per share.
His trading history shows five years of losses. Overall, he averaged a loss of 39% on 533,818 shares bought at an average price of $2.41 per share. He also lost 22% on 157,168 shares sold at an average price of $1.89 per share.
Check out the other guru stakeholder. There is no insider trading to report.
Historical share price, revenue and net income tracking:
Highlight: Amyris Inc. (AMRS, Financial)
The current AMRS share price is $2.38, or 42.7% off the 52-week high of $4.15.
Down 22% over 12 months, Amyris Inc. has a market cap of $181.39 million, and trades with a P/B of 8.68.
Formed in 2003, Amyris Inc. is a renewable products company that provides alternatives to petroleum-sourced products used in transportation fuel markets and specialty chemical. The company uses its proprietary synthetic biology platform to design microbes, primarily yeast organisms, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. These long-chain hydrocarbons are used in many products including cosmetics, lubricants, flavors and fragrances, polymers and plastic additives, home and personal care products and transportation fuels.
The company reported aggregate revenue of $10.8 million for the quarter ending June 30, 2013, down from $19.3 million year over year. The company reports a GAAP net loss of $38.9 million for the quarter, up from a loss of $46.8 million in the same quarter of 2012. The net loss attributable to common stockholders is reported at ($0.34 per share) for the second quarter of 2013.
Guru Action: The sole guru stakeholder, as of June 30, 2013, is Paul Tudor Jones with 11,600 shares or 0.02% of shares outstanding.
His trading history shows losses in seven out of seven quarters. Overall, he averaged a loss of 14% on 20,600 shares bought at an average price of $2.78 per share. He also lost 26% on 9,000 shares sold at an average price of $3.21 per share.
Check out the other guru histories and insider trading.
Historical share price, revenue and net income tracking:
Highlight: StemCells Inc. (STEM)
The current STEM share price is $1.43, or 42.8% off the 52-week high of $2.50.
Down 36% over 12 months, StemCells Inc. has a market cap of $59.07 million, and trades at a P/B of 6.89.
StemCells Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. The company’s primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents.
On Oct. 8, 2013, the company reported closing its $18.6 million public offering. Selling units at a public offering price of $1.45 per unit, StemCells Inc. received total proceeds of around $17.3 million after expenses, according to a company press release.
Guru Action: There is no recent guru action to report. Jim Simons sold out his holding in the first quarter of 2013. He took a loss of 19.2% on 24,300 shares sold at an average price of $1.77.
His trading history shows 11 losing quarters out of 13 quarters total. In the first and second quarters of 2012, he gained 44.4% and 72.3%, respectively.
Check out the histories of past guru stakeholders. There is no insider activity to report.
Historical share price, revenue and net income tracking since 1992:
If you are not yet a Premium Member, try a 7-day Free Trial.
Use the GuruFocus Value Screen to find 52-Week Lows and discover potentially deep value stocks held by billionaire Guru investors.
